High risk of in-breast tumor recurrence after BRCA1/2-associated breast cancer
Martin Nilsson(Lund University), Niklas Loman(Lund University), Åke Borg(Lund University), Ulf Kristoffersson, Karin Henriksson(Uppsala University Hospital), Óskar Þór Jóhannsson(National University Hospital of Iceland), Håkan Olsson(Nokia (Finland)), Linda Hartman(Lund University), Elsa Lanke(Lund University)
Cited by 56
Related Papers
Average Risks of Breast and Ovarian Cancer Associated with BRCA1 or BRCA2 Mutations Detected in Case Series Unselected for Family History: A Combined Analysis of 22 Studies
|The American Journal of Human Genetics|2003|3.7k
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
|The Lancet|2010|2.3k
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline <i>BRCA1/2</i> Mutation
|Journal of Clinical Oncology|2014|1.7k
The Life History of 21 Breast Cancers
|Cell|2012|1.5k